[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][N][Branch2][Branch1][P][C][C][N][Branch2][Branch1][Branch1][C][C][N][Branch2][Ring2][=Branch2][C][C][N][Ring1][N][C][C][=Branch1][C][=O][N][C][C][C][C][C][C][N][C][C][C][C][C][C@H1][C@@H1][C@H1][Branch1][Branch1][C][S][Ring1][Branch1][N][C][=Branch1][C][=O][N][Ring1][Branch2][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1].[177Lu+3]"}, {"from": "gpt", "value": "The molecule is a radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication."}]